A Phase 2 interventional study of SMUP-IA-01(low-dose) and SMUP-IA-01(mid-dose) in Knee Osteoarthritis, sponsored by Medipost Co Ltd.. Active, not recruiting at 5 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-02-07.
Sponsored by Medipost Co Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of — 13 open to participants now, 21 under way, 4 of them phase 3. Osteoarthritis, Knee · Korea, Republic of.
Among the 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of, this one is the 55th largest by enrollment of the 85 interventional ones that give a count, is one of 5 that started in 2023, is one of 14 in phase 2, reaches primary completion later than 14 of the 20 other live ones, and was the 86th registered.
3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.
Browse Osteoarthritis, Knee studies →13 of the 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 40–75
Yonsei University · Sites in Korea, Republic of
Ages 40–70
Kang Stem Biotech Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Yonsei University · Sites in Korea, Republic of
Ages 19+
Glaceum · Sites in Korea, Republic of
Ages 40–75
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
96 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 21 · Phase 3 20 · Phase 4 17
First in 2005; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is above the median of 68 across 2,717 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 124 across the 85 interventional studies, 50 across the 11 observational. Of the 54 that completed or were terminated, 9 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 96 have an industry lead sponsor. The 10 most frequent:
Medipost Co Ltd. is the lead sponsor of 17 studies on the registry; 1 is open to participants now.
Medipost Co Ltd. has 4 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
6 of the studies in Osteoarthritis, Knee with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04427930Phase 3R-BioFollow-up Study for Participants of Jointstem Phase 3 Clinical Trial | 2026-12-23 |
| NCT04368806Phase 3Nature Cell Co. Ltd.A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis | 2027-08-06 |
| NCT07267793DALIM TISSEN Co., Ltd.Long-Term Study of CartiPRO for Knee Pain Due to Osteoarthritis or Cartilage Damage | 2026-12 |
| NCT07367789Yonsei UniversityPrediction of Postoperative Outcomes After TKA Using Instrumented Insoles and DNN | 2026-12-31 |
| NCT06798727Medipost Co Ltd.Evaluation Safety and Explore Efficacy Long-term Follow-up Study on Subjects Receiving SMUP-IA-01 or Active Control | 2027-03-20 |
Add all 6 to your calendar (.ics) → With an account.
Among the 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a follow-up study to investigate the long-term safety and explore efficacy of SMUP-IA-01, for the treatment of Knee Osteoarthritis. Subjects who participated in and completed the initial stage of the Phase II trial (NCT05182034) will be followed-up until 60 months.
The subjects will be followed up at 12-month, 24-month, 36-month, 48-month and 60-month after the initial administration of SMUP-IA-01.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A single knee administration of SMUP-IA-01 (low-dose, 4.0 x 10\^6 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
Biological: SMUP-IA-01(low-dose)
A single knee administration of SMUP-IA-01 (mid-dose, 1.0 x 10\^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
Biological: SMUP-IA-01(mid-dose)
A single knee administration of High Hyal Plus Inj.(1% Sodium Hyaluronate 20mg/2ml)
Drug: High Hyal Plus
A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
Also known as: Human umbilical cord blood-derived mesenchymal stem cells
A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
Also known as: Human umbilical cord blood-derived mesenchymal stem cells
A single knee administration of Hyaluronic acid(1% Sodium Hyaluronate 20mg/2ml)
Change of total score in WOMAC (Western Ontario and McMaster University)
Comparing WOMAC total score changes with baseline scores of SMUP-IA-01 phase I trial and scores of f/u study at 12 months, 24 months, 36 months, 48 months and 60months after treatment (score range 0-96, higher score represent worse symptoms).
Time frame: Time Frame: Month 12, 24, 36, 48 and 60 after treatment
Change of score in WOMAC three subscales (Pain, stiffness, physical function) aginst MP-SMUP-IA-01-P02's baseline.
The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68).
Time frame: Time Frame: Month 12, 24, 36, 48 and 60 after treatment
Change of score in 100 mm VAS (Visual Analogue Scale)
The score ranges from "0" or no pain to "100" very severe pain
Time frame: Time Frame: Month 12, 24, 36, 48 and 60 after treatment
Change of score in IKDC(International Knee Documentation Committee)
The scores for each category are summed up and divided into 87, which is the maximum score possible, and then is evaluated by converting it into a scale of 100 points. Higher score indicates better function and less symptoms for the knee.
Time frame: Time Frame: Month 12, 24, 36, 48 and 60 after treatment
Change of score in WORMS(Whole-Organ Magnetic Resonance iMaging Score)
For structural and tissue evaluation of knee, MRI image of detailed knee parts are graded from min. 0 to max. 6. Lower number indicate normal status
Time frame: Time Frame: Month 12 and 24 after treatment
Change in K&L(Kellgren-Lawrence) grade
The K \& L grade is 0 to 4 Grade, which means that the higher the grade, the greater the joint damage and the stenosis of the joint
Time frame: Time Frame: Month 12, 24 and 60 after treatment
Change in joint space width
Evaluation of disease progression in target knee as ascertained by change from baseline in joint space width (JSW) determined using radiography
Time frame: Time Frame: Month 12, 24 and 60 after treatment
Change in mechanical axis, anatomical axis
The degree of deformation of the lower half of the body is measured by measuring the angles of the mechanical axis and the anatomical axis with respect to the vertical axis. Mechanical axis: A line connecting the femoral head center point and the ankle joint center point. Anatomical axis: The middiaphyseal line of the femur and tibia
Time frame: Time Frame: Month 12, 24 and 60 after treatment
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Mar 2027, 48 months after the start.
Of 58 industry-sponsored phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 25. This study's planned 48 months is above that.
Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medipost Co Ltd.